Hematology, Transfusion and Cell Therapy最新文献

{"title":"Lower doses of dacarbazine (modified BEACODD) as a safer strategy with equal effectiveness in an intensive treatment protocol of Hodgkin's lymphoma: a preliminary retrospective analysis of a single public center in Brazil","authors":"Larissa Hilario Dulley ,&nbsp;Arthur Gomes Oliveira Braga ,&nbsp;Guilherme Garcia Rodrigues ,&nbsp;Sergio Costa Fortier ,&nbsp;Carlos Sérgio Chiattone ,&nbsp;Talita Maira Bueno da Silveira","doi":"10.1016/j.htct.2024.06.003","DOIUrl":"10.1016/j.htct.2024.06.003","url":null,"abstract":"<div><div>The German Hodgkin Study Group developed the escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) protocol as a treatment strategy for advanced-stage Hodgkin's lymphoma. In Brazil, as well as in other countries, procarbazine has been replaced with dacarbazine due to the limited availability of procarbazine. The Hematology Center at Irmandade da Santa Casa de Misericórdia in São Paulo adopted and modified the escalated BEACOPP protocol, substituting prednisone with dexamethasone and incorporating two different doses of dacarbazine: 375 mg/m²/day on Day 8 or the original dose of 250 mg/m²/day on Days 2 and 3. This adjustment was made in response to the anticipated toxicity profile. This study aimed to compare the two different doses in the protocols (375 mg/m²/cycle versus 500 mg/m²/cycle) administered to patients with advanced Hodgkin's lymphoma in similar periods. This retrospective study analyzed the data of 31 patients at a single center in Brazil from 2019 to 2021. Seventeen of the 31 patients received 500 mg/m²/cycle (500 Group), while 14 received 375 mg/m²/cycle (375 Group). At the end of the protocol, 71% of the patients in the 375 Group and 76% in the 500 Group achieved complete remission. On analyzing the number of cycles that patients presented with febrile neutropenia, the 500 Group had three times more events (17.9%) than the 375 Group (6.09% - p-value = 0.04). In the 500 Group, 47.1% needed to change the protocol to ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, and dacarbazine) due to toxicity. In this limited cohort from a single public center in Brazil, the use of 375 mg/m² of dacarbazine per cycle of the modified escalated BEACOPP protocol emerged as a safer strategy, maintaining treatment efficacy without compromising response in patients with advanced Hodgkin's lymphoma.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103682"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An approach to autologous stem cell mobilization: trying to define good mobilizers","authors":"Sara Montolio Chiva,&nbsp;Paula Gomez Fernandez,&nbsp;Antonio Manuel Gutiérrez Garcia,&nbsp;Maria del Carmen Ballester Ruiz,&nbsp;Antonia Sampol Mayol,&nbsp;Albert Perez Montaña","doi":"10.1016/j.htct.2024.04.126","DOIUrl":"10.1016/j.htct.2024.04.126","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Stem cell mobilization is a well-known procedure to harvest hematopoietic stem cells for autologous stem cell transplantation in certain hematologic diseases. Numerous studies have been conducted to identify risk factors for poor mobilization but there are no studies that identify good mobilizers. In our hospital, we decided to explore good mobilizers, defining them as those with ≥40 CD34⁺ cells/μL on Day +4 in order to start early apheresis.</div></div><div><h3>Material and methods</h3><div>A descriptive retrospective study was performed at Hospital Universitari Son Espases. A total of 198 patients mobilized with doses of around 10 µg/kg of granulocyte colony-stimulating factor (G-CSF) every 12 h were analyzed for autologous collection between January 2015 and September 2022. Fifty patients who had ≥40 CD34⁺ cells/μL on Day +4 started early apheresis; the rest continued mobilization as planned. Success was defined as obtaining over 2.5 × 10⁶ CD34⁺ cells/kg in a single apheresis.</div></div><div><h3>Results</h3><div>The necessary number of CD34⁺ cells/kg to perform an autologous stem cell transplantation was reached in a single apheresis session in 62 % of patients with ≥40 CD34⁺ cells/μL in peripheral blood. A cutoff of 102 CD34⁺ cells/μL on Day +4 was shown to have the best success rate (94 %)<strong>.</strong> In an analysis of success, age, previously failed mobilization and having one or more adverse factors for bad mobilization were statistically significant.</div></div><div><h3>Conclusion</h3><div>Patients considered as good mobilizers were matched with our factors of poor mobilization, revealing that most patients (79 %) had none or only one risk factor for poor mobilization. Apheresis on Day +4 in good mobilizers was shown to be an effective alternative to reduce mobilization duration and decrease the amount of granulocyte-colony stimulating factor administered.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103688"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the role of bronchoscopy in the management of patients with acute leukemia—a transversal study and proposal of evaluation","authors":"José Vanildo Rodrigues de Oliveira ,&nbsp;Carlos Wilson de Alencar Cano ,&nbsp;José Vivaldo Moreira Feitosa Júnior ,&nbsp;Guilherme Carneiro Barreto ,&nbsp;Fernanda Rodrigues Mendes ,&nbsp;Raphael Costa Bandeira de Melo ,&nbsp;Elvira Deolinda Rodrigues Pereira Velloso ,&nbsp;Vanderson Rocha ,&nbsp;Eduardo Magalhães Rego ,&nbsp;Wellington Fernandes da Silva","doi":"10.1016/j.htct.2025.103741","DOIUrl":"10.1016/j.htct.2025.103741","url":null,"abstract":"<div><h3>Introduction</h3><div>Bronchoscopy is frequently performed in the management of patients with acute leukemia due to their high susceptibility to infections. In this setting, it is performed in the context of lung infiltrates on imaging and persistent fever in immunocompromised subjects. This study aimed to evaluate the utility of bronchoscopy in patients with acute leukemia, its diagnostic yield, and its impact on management decisions.</div></div><div><h3>Methods</h3><div>This is a single-center cross-sectional study that included patients diagnosed with acute leukemia of any phenotype who received intensive chemotherapy. Consecutive patients who underwent bronchoscopy as part of a work-up for associated infections were selected, while patients who had undergone bone marrow transplant were excluded. This study investigated patient characteristics and the impact of bronchoscopy on changes in clinical management.</div></div><div><h3>Results</h3><div>Seventy-nine patients who underwent bronchoscopy at various stages of treatment were analyzed. The most frequent type of acute leukemia was acute myeloid leukemia, accounting for 68.3 % of cases. The induction phase was the most prevalent (29.1 %) treatment stage. Bacterial cultures were positive in 17 out of the 74 patients evaluated, with <em>Pseudomonas aeruginosa</em> being the most frequently identified microorganism<em>.</em> A change in medical management was observed in 18.2 % of cases, and only six patients experienced secondary complications.</div></div><div><h3>Conclusions</h3><div>This is the first Brazilian study to evaluate the utility of bronchoscopy in managing infectious complications in patients with acute leukemia. The impact of bronchoscopy on clinical management was less than anticipated, largely due to its low yield in identifying causative agents. Nevertheless, it remains a safe procedure and can be useful in specific situations.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103741"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare case of discrepant ABO typing between mother and newborn caused by para-Bombay AB phenotype","authors":"Tatiane Aparecida de Paula Vendrame ,&nbsp;Giovana Faria Devides ,&nbsp;Nayara Morais Silva ,&nbsp;Marcela Custódio Mendes ,&nbsp;Márcia Léia Morais Sampaio ,&nbsp;Marcia Miyuki Nakamura ,&nbsp;Greice Ap.Chetta de Klerk ,&nbsp;Lilian Castilho ,&nbsp;Afonso Cortez ,&nbsp;Flavia Roche Moreira Latini ,&nbsp;Carine Prisco Arnoni","doi":"10.1016/j.htct.2025.103742","DOIUrl":"10.1016/j.htct.2025.103742","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103742"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of circulating anaplastic lymphoma kinase-negative anaplastic large cell lymphoma","authors":"Radu Chiriac,&nbsp;Lucile Baseggio","doi":"10.1016/j.htct.2025.103743","DOIUrl":"10.1016/j.htct.2025.103743","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103743"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the role of serum soluble ST2 as a diagnostic biomarker for cancer-associated venous thromboembolism","authors":"Eman Mohamed Abdellatif,&nbsp;Emad Hamdy Hamouda Mohammed,&nbsp;Azza Mohamed Amin Darwish","doi":"10.1016/j.htct.2025.103740","DOIUrl":"10.1016/j.htct.2025.103740","url":null,"abstract":"<div><h3>Introduction</h3><div>Venous thromboembolism, a common complication associated with cancer, causes increased morbidity and mortality. D-dimer levels are often increased non-specifically in cancer which limits their use to diagnose venous thromboembolism. The current study aimed to investigate the role of the serum soluble suppression of tumorigenicity 2 (sST2) as a new biomarker to diagnose venous thromboembolism in cancer.</div></div><div><h3>Methods</h3><div>Eighty-eight patients with different types of cancer were enrolled and divided into two groups: Group I: 44 cancer patients with confirmed diagnosis of venous thromboembolism and Group II: 44 age- and sex-matched cancer patients without any thrombotic complications. The D-dimer test and sST2 measurement were performed for all study subjects.</div></div><div><h3>Results</h3><div>Serum sST2 levels were significantly higher in Group I than in Group II (<em>p</em>-value &lt; 0.001); the median serum sST2 was 13.02 ng/mL (range: 7.65–117.9 ng/mL) in Group I versus 8.56 ng/mL (range: 5.59–10.33 ng/mL) in Group II. There was a significant positive correlation between serum sST2 and the D-dimer level. Using a receiver operating characteristic curve, sST2 had a greater area under the curve than the D-dimer test (0.974 versus 0.869, respectively). Although the D-dimer test was more sensitive, sST2 had a greater specificity than D-dimer (95.45 % versus 27.3 %, respectively) and a higher positive predictive value (95.3 % versus 56.8 %, respectively).</div></div><div><h3>Conclusion</h3><div>The results of the current study support a potential role of soluble ST2 to aid in diagnosing venous thromboembolism in cancer patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103740"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When innovation meets patient blood management – a new way to see bleeding","authors":"Guilherme Rabello ,&nbsp;Rosangela Monteiro ,&nbsp;Bianca Meneghini ,&nbsp;Fabio Biscegli Jatene","doi":"10.1016/j.htct.2024.07.002","DOIUrl":"10.1016/j.htct.2024.07.002","url":null,"abstract":"<div><div>The first step in innovation is to identify a problem of real relevance and systematically address it to deliver a sophisticated and viable solution. Disruptive innovation is a process where technology, products, or services are transformed or replaced by a better innovative solution. This superiority must be perceived by users as being more accessible, simple, or convenient. Patient Blood Management (PBM) suggests the notion of the timely application of evidence-based medical and surgical concepts designed to maintain hemoglobin concentration, optimize hemostasis and minimize blood loss thus improving patient outcomes, that is, they are aimed at changing patient care, assisting healthcare professionals in disease treatment and cure as well as risk reduction. Thus, innovation in PBM is a new frontier to be pursued. The management of patient's blood and preparation for surgical procedures is an enormous challenge that helps minimize anemia and control blood loss during hospitalization, ensuring they are discharged in adequate clinical conditions. Until 2016, there was no standard definition or classification for the severity of intraoperative bleeding or hemostasis. The development of a PBM program when combined to the development of a bleeding scale such as the validated Intraoperative Bleeding (VIBe) Scale, represents a new solution that balances perioperative blood loss and more importantly, enables a critical cultural change which can be useful to help surgeons communicate anticipated hemostatic needs throughout a case and therefore enhance efficiency leading to better outcomes.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103691"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FLT3-ITD POSITIVE ACUTE MYELOİD LEUKEMIA MIMICKING ACUTE PROMYELOCYTIC LEUKEMİA","authors":"Birsen Sahip Yesiralioğlu ,&nbsp;Müzeyyen Aslaner Ak","doi":"10.1016/j.htct.2024.11.020","DOIUrl":"10.1016/j.htct.2024.11.020","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Acute myeloid leukemia (AML) is a heterogeneous disease due to genetic abnormalities and differences in immunophenotypes. The diagnosis of AML requires a careful evaluation of clinical morphology, immunophenotyping, cytogenetics, and molecular analyses. &lt;sup&gt;1&lt;/sup&gt; In current practice, flow cytometry-based immunophenotyping provides a rapid and reliable method for diagnosing AML, including acute promyelocytic leukemia (APL). APL is a subtype of AML with distinct morphological, biological, and clinical characteristics. It can be effectively treated with ATRA-based therapy protocols. However, if not treated quickly, it can be fatal due to the risk of disseminated intravascular coagulation (DIC). Therefore, the diagnosis and treatment of APL represent a true medical emergency.&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt;&lt;div&gt;The absence of CD34, HLA-DR, and CD11b is a characteristic immunophenotypic feature that often distinguishes APL from other AML subtypes. However, AML subtypes other than APL that lack CD34 and HLA-DR expression have also been reported. APL accounts for 8% to 17% of AML patients. In AML patients without the PML-RARA fusion gene, 12% to 21% of cases have been identified as HLA-DR negative. These HLA-DR negative AML cases are distinct from APL because they do not carry the characteristic PML-RARA fusion.&lt;sup&gt;3&lt;/sup&gt;&lt;/div&gt;&lt;div&gt;HLA-DR and CD34 negativity is generally observed in AML-M1 and AML-M2 subtypes and is associated with nucleophosmin (NPM1) gene mutations and FMS-like tyrosine kinase-internal tandem duplication (FLT3-ITD) mutations.&lt;sup&gt;4&lt;/sup&gt; NPM1 mutations are among the most common genetic abnormalities in AML, occurring in 27-35% of adult AML cases. Although rare, an \"APL-like\" immunophenotype has been reported in some de novo acute myeloid leukemia (AML) cases with NPM1 gene mutations. These cases show some immunophenotypic similarities to APL, despite being genetically different. AML cases with NPM1 mutations have unique clinical and biological characteristics.&lt;sup&gt;5&lt;/sup&gt;&lt;/div&gt;&lt;div&gt;In this study, we aimed to highlight the association of FLT3-ITD positivity, as opposed to NPM1, in HLA-DR negative non-APL AML cases in our clinic.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methodology&lt;/h3&gt;&lt;div&gt;We examined three acute leukemia patients who were referred to our clinic within one month and were initially reported as APL based on flow cytometry analysis. Our focus on these patients stemmed from the fact that a condition with an incidence of 1-2 cases per 1 million people per year was diagnosed consecutively as APL in flow cytometry analysis within a short period. Fluorescent in situ hybridization (FISH) analysis for the 15;17 translocation and polymerase chain reaction (PCR) for FLT3-ITD and FLT3-TKD mutations were performed on the patients' peripheral blood. NPM1 mutations could not be analyzed in these patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Morphological examination of the patients' peripheral blood smears showed prominent nucleoli, Au","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"46 ","pages":"Pages S38-S39"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143339825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THE PROGNOSTIC ROLE OF WHOLE BLOOD VISCOSITY AND BONE MARROW FIBROSIS IN PREDICTING SURVIVAL OUTCOMES IN NEW DIAGNOSIS MULTIPLE MYELOMA PATIENTS","authors":"Mustafa Duran","doi":"10.1016/j.htct.2024.11.011","DOIUrl":"10.1016/j.htct.2024.11.011","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to evaluate the prognostic role of whole blood viscosity and bone marrow fibrosis in predicting survival outcomes and relationships with prognostic predictors, such as international scorin system albumin levels, beta2-microglobulin, total protein, albumin and lactate dehydrogenase in newly diagnosed multıple myeloma patients.</div></div><div><h3>Case report</h3><div>Methodology</div><div>We retrospectively evaluated 108 patients diagnosed with multıple myeloma between 2015-2022. Whole blood viscosity was calculated using the Simone formula, incorporating the haematocrit and total protein values. Bone marrow fibrosis was graded as mild (2), significant(3), or advanced. Comparisons of grade 0-3 bone narrow fibrosis and high-low calculated whole blood viscosity groups in terms of overall survival were conducted using the Kaplan-Meier survival curve and log-rank test.</div></div><div><h3>Results</h3><div>The median follow-up period was 16 months, and 57.4% of patients died during follow-up. The median overall survival was 26 months. The calculated whole blood viscosity (c-WBV) value predicted mortality with 88.7% sensitivity and 45.7% specificity. Patients with a high c-WBV (≥17.14 208 mPa-s) had significantly lower one- and two-year survival rates than those with a low c-WBV (&lt;17.14 208 mPa-s) (p&lt;0.001). Bone narrow fibrosis was inversely related to survival, with higher grades being associated with lower survival rates. The two-year expected survival time respectively bone narrow fibrosis 2 and 3 was determined to be 56.7% and 43.6% 41.4% and 23.3% (p&lt;0.001). This study highlights the potential of whole blood viscosity and bone narrow fibrosis as prognostic markers in patients with newly diagnosed multıple myeloma patients.</div></div><div><h3>Conclusion</h3><div>Incorporating these parameters into the existing staging systems may enhance prognostic prediction and guide treatment decisions. Further prospective studies are warranted to validate these findings and explore the mechanistic links between whole blood viscosity, bone narrow fibrosis, and MM pathophysiology.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"46 ","pages":"Page S29"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143340071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RESULTS OF UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE","authors":"Muhammed Murati ,&nbsp;Yakup Ünsal ,&nbsp;Güler Delibalta ,&nbsp;Serdar Bedii Omay","doi":"10.1016/j.htct.2024.11.013","DOIUrl":"10.1016/j.htct.2024.11.013","url":null,"abstract":"<div><h3>Objective</h3><div>Evaluation of data from unrelated hematopoietic stem cell transplants performed in our transplant center.</div></div><div><h3>Methodology</h3><div>At the Private Emsey Hospital Adult Stem Cell Transplantation Unit were evaluated retrospectively between 2016 and 2023 to Allogeneic hematopoietic stem cell transplantations performed on 76 patients with different diagnoses from unrelated donors.</div></div><div><h3>Results</h3><div>Data of patients with a mean age of 41.9 years were retrospectively analyzed. All donors were from a Turkish stem cell bank and 51% had HLA 1 allele incompatibility. 28 transplants were performed between different genders. Average follow-up was 17.3 months. Neutrophil engraftment occurred in an average of 18.1 days. Acute GVHD was detected in 26% and chronic GVHD in 41%. 1-year overall survival was 37% and disease-free survival was 32%.</div></div><div><h3>Conclusion</h3><div>Non-relative stem cell transplantation is an important option especially in hematological diseases where there is no family donor and allogeneic transplantation is required. It has been observed that non-relative data performed in our clinic are similar to data from other centers.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"46 ","pages":"Page S31"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143340074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}